Prothena Corp shares climbed 5% in after-hours trading on Friday after the company said it expects to reduce its 2025 net cash burn from operating and investing activities to between $170 million and ...

Shares of Prothena Corporation PRTA plummeted 53.5% year to date compared with the industry’s decline of 0.6%. The recent ...

Prothena (PRTA): Roche and Bristol Myers have collaborations with Prothena for the Parkinson's and Alzheimer's treatments, respectively. See why Prothena may be well positioned here.

Because of this, Prothena's PRX012 now has the potential to benefit from a similar accelerated approval. As the company continues efforts to show further evidence that PRX012 successfully reduces ...

It has been about a month since the last earnings report for Prothena (PRTA). Shares have added about 36.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

Prothena PRTA shares ended the last trading session 12.3% higher at $39.62. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Prothena is a biotech with a unique, epitope targeting approach to drug development. It could earn billions in milestone payments over the next few years, and may become profitable in FY21.

Prothena responded by ending all development of birtamimab and, a few months later, by laying off 57% of its employees. Yet, in 2021, Prothena resurrected the program in response to a post hoc ...

Prothena is laying off almost two-thirds of its workforce as the Irish biotech navigates the fallout from giving up on its failed amyloidosis drug.. In May, the company announced the failure of ...

Trade-Ideas LLC identified Prothena (PRTA) as a strong on high relative volume candidate. Skip to main content. PREMIUM PRODUCTS.

Shares of late-stage clinical biotechnology Prothena PRTA surged 88.7% in a year against the industry’s decline of 12.6%. The significant surge is mostly attributable to Prothena’s robust ...

Prothena reported unfavorable data from a Phase 3 trial of birtamimab to treat the blood disorder AL amyloidosis. The study didn't meet its primary endpoint of time to all-cause mortality, ...